Point Therapeutics to Host First Quarter 2006 Results Conference Call/Audio Webcast
May 04 2006 - 7:30AM
Business Wire
Point Therapeutics, Inc. (NASDAQ: POTP), announced today that it
will release first quarter 2006 results on Tuesday, May 9, 2006,
after the close of the U.S. financial markets. A conference call
will follow at 4:30 PM Eastern Time, to review the results and
provide an update on the Company's progress. -0- *T Participants
are invited to attend the call by visiting www.pther.com or by
dialing: 1-800-299-0433 (International: 617-801-9712) Passcode:
23190397 A re-broadcast of the conference call will be available
until May 16, 2006 and accessible by dialing: 1-888-286-8010
(International: 617-801-6888) Passcode: 69522614 *T About Point
Therapeutics, Inc.: Point is a Boston-based biopharmaceutical
company developing a portfolio of dipeptidyl peptidase (DPP)
inhibitors for use in cancer, type 2 diabetes and as vaccine
adjuvants. Point is currently studying its lead product candidate,
talabostat, in two Phase 3 trials in non-small cell lung cancer.
Point is also studying talabostat in several Phase 2 trials,
including as a single-agent in metastatic melanoma, in combination
with cisplatin in metastatic melanoma, in combination with
rituximab in advanced chronic lymphocytic leukemia, and in
combination with gemcitabine in metastatic pancreatic cancer. In
addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes, and PT-510 as
a vaccine adjuvant.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024